Not sure what article you read. Phase II trials just wrapped up and showed both tolerability and effectiveness, hitting primary endpoints. Phase III is apparently recruiting, which should reveal any showstopper side effects in a larger and more diverse population. It’s realistic this could hit the market in 3-5 years or less.

Additional info: https://www.fiercebiotech.com/biotech/british-biotech-levice...